TY - JOUR T1 - Novel risk factors for Coronavirus disease-associated mucormycosis (CAM): a case control study during the outbreak in India JF - medRxiv DO - 10.1101/2021.07.24.21261040 SP - 2021.07.24.21261040 AU - Umang Arora AU - Megha Priyadarshi AU - Varidh Katiyar AU - Manish Soneja AU - Prerna Garg AU - Ishan Gupta AU - Vishwesh Bharadiya AU - Parul Berry AU - Tamoghna Ghosh AU - Lajjaben Patel AU - Radhika Sarda AU - Shreya Garg AU - Shubham Agarwal AU - Veronica Arora AU - Aishwarya Ramprasad AU - Amit Kumar AU - Rohit Kumar Garg AU - Parul Kodan AU - Neeraj Nischal AU - Gagandeep Singh AU - Pankaj Jorwal AU - Arvind Kumar AU - Upendra Baitha AU - Ved Prakash Meena AU - Animesh Ray AU - Prayas Sethi AU - Immaculata Xess AU - Naval Vikram AU - Sanjeev Sinha AU - Ashutosh Biswas AU - Alok Thakar AU - Sushma Bhatnagar AU - Anjan Trikha AU - Naveet Wig Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/26/2021.07.24.21261040.abstract N2 - Background The epidemiology of the Coronavirus-disease associated mucormycosis (CAM) syndemic is poorly elucidated. We aimed to identify risk factors that may explain the burden of cases and help develop preventive strategies.Methods We performed a case-control study comparing cases diagnosed with CAM and those who had recovered from COVID-19 without developing mucormycosis (controls). Information on comorbidities, glycemic control, and practices related to COVID-19 prevention and treatment was recorded.Results 352 patients (152 cases and 200 controls) diagnosed with COVID-19 during April-May 2021 were included. In the CAM group, symptoms of mucormycosis began a mean 18.9 (SD 9.1) days after onset of COVID-19, and predominantly rhino-sinus and orbital involvement was present. All, but one, CAM cases carried conventional risk factors of diabetes and steroid use. On multivariable regression, increased odds of CAM were associated with the presence of diabetes (adjusted OR 3.5, 95%CI 1.1-11), use of systemic steroids (aOR 7.7,95% CI 2.4-24.7), prolonged use of cloth and surgical masks (vs no mask, aOR 6.9, 95%CI 1.5-33.1), and repeated nasopharyngeal swab testing during the COVID-19 illness (aOR 1.6,95% CI 1.2-2.2). Zinc therapy, probably due to its utility in immune function, was found to be protective (aOR 0.05, 95%CI 0.01-0.19). Notably, the requirement of oxygen supplementation or hospitalization did not affect the risk of CAM.Conclusion Judicious use of steroids and stringent glycemic control are vital to preventing mucormycosis. Use of clean masks, preference for N95 masks if available, and minimizing swab testing after the diagnosis of COVID-19 may further reduce the incidence of CAM.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone to declareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institute Ethics Committee of AIIMS, Ansari Nagar, Delhi, India on 28/05/2021. The reference number for the approval is IECPG-353/28.05.21.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available upon request to the corresponding author, along with a proposed research question explaining the request for data. ER -